Research & Development

What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,

In the intricate landscape of drug discovery, pinpointing effective inhibitors for Protein Tyrosine Phosphatase 1B (PTP1B) stands as a monumental challenge with profound implications for treating metabolic disorders such as diabetes and obesity. PTP1B is a key player in regulating insulin signaling

Imagine a scenario where a patient diagnosed with metastatic colorectal cancer (CRC) receives a treatment that not only halts the disease's progression but also leads to remarkable tumor shrinkage, offering a renewed chance at life. This isn’t just a hopeful vision but a reality for a small subset

The alarming statistic that individuals with type 1 diabetes face a 4.29-fold increased risk of developing bladder cancer has sent ripples through the medical community, challenging long-held assumptions about the intersection of metabolic disorders and malignancies. With bladder cancer already

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose pioneering work in technology and innovation has pushed boundaries in medical research and development. With a deep focus on cutting-edge solutions, Ivan has been at the forefront of exploring focused ultrasound as a

Imagine a world where life-saving cancer treatments no longer require weeks of waiting for cell processing or come with a price tag in the hundreds of thousands of dollars, but instead can be administered in days at a fraction of the cost. This is the promise of in vivo CAR cell therapy, an